Associated Papers
Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients.
Puli'uvea C et al.
Hematology (amsterdam, Netherlands), 2024
38197452 (PubMed )
Supplement: supplement_1.docx
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
37629188 (PubMed )
Supplement: ijms-24-13008-s001.zip › ijms-2555672-supplementary.pdf
Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing.
Abelson S et al.
Science Advances, 2020
33298453 (PubMed )
Supplement: abe3722_Table_S3.xlsx › tab2
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Annunziato S et al.
Nature Communications, 2019
30674894 (PubMed )
Supplement: 41467_2019_8301_MOESM1_ESM.pdf
Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
Maslah N et al.
Annals of Hematology, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 13
Somatic mutation driven codon transition bias in human cancer.
Son H et al.
Scientific Reports, 2017
Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS et al.
British Journal of Haematology, 2017
Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.
Lippert E et al.
Haematologica, 2014
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
Govindan R et al.
Cell, 2012
Select a paper to view details